VITR Share Price Performance
SEK 0
-208.60 (-100.00%)
Price SEK 0
Fair ValueSEK 188.75
Share Pricen/a
There's No Escaping Vitrolife AB (publ)'s (STO:VITR) Muted Revenues
Dec 18
Vitrolife AB (publ) Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 5 Fair Values set on narratives written by author
VITR Community Narratives
AN
Fair Value SEK 188.75 30.9% undervalued intrinsic discount
Profit Margins And Revenue Outlook Will Support Recovery Trends Ahead
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
Fair Value SEK 230 43.3% undervalued intrinsic discount
IVF Technology Adoption And Genetic Testing Demand Will Drive Strong Long-Term Upside
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value SEK 141 7.4% undervalued intrinsic discount
IVF Cycle Recovery And Consumables Momentum Will Support A Fairly Valued Outlook
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
IVF Cycle Recovery And Consumables Momentum Will Support A Fairly Valued Outlook
Catalysts About Vitrolife Vitrolife provides products and services used in IVF clinics, including media, disposable devices, lab technologies and genetic testing. What are the underlying business or industry changes driving this perspective?Read more
2
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
SEK 141
7.4% undervalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
8.42% p.a.
Profit Margin
19.67%
Future PE
25.35x
Price in 2029
SEK 164.57
Profit Margins And Revenue Outlook Will Support Recovery Trends Ahead
Key Takeaways Recovery in IVF procedure volume and expansion in key regions will drive organic revenue growth and margin improvement as market conditions stabilize. Product innovation, increased reimbursement support, and automation investments will enhance customer retention and support long-term international sales growth.Read more
52
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
SEK 188.75
30.9% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
7.49% p.a.
Profit Margin
19.15%
Future PE
35.66x
Price in 2028
SEK 219.64
IVF Technology Adoption And Genetic Testing Demand Will Drive Strong Long-Term Upside
Catalysts About Vitrolife Vitrolife develops and supplies advanced IVF media, consumables, technologies, and genetic testing solutions that support clinics across the full reproductive care workflow. What are the underlying business or industry changes driving this perspective?Read more
4
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
SEK 230
43.3% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
7.74% p.a.
Profit Margin
21.03%
Future PE
39.44x
Price in 2028
SEK 268.66
Trending Discussion
Recently Updated Narratives
AN
IVF Cycle Recovery And Consumables Momentum Will Support A Fairly Valued Outlook
Fair Value: SEK 141 7.4% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
VITR: Restructuring And Goodwill Impairment Will Support Future Upside Potential
Fair Value: SEK 188.75 30.9% undervalued intrinsic discount
3 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
IVF Technology Adoption And Genetic Testing Demand Will Drive Strong Long-Term Upside
Fair Value: SEK 230 43.3% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Vitrolife AB (publ) Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
Feb 03, 2026
- 3.25
- 58.91%
- 12.55%
- 14.1%
About VITR
- Founded
- 1989
- Employees
- 1100
- CEO
- WebsiteView website
Vitrolife AB (publ) provides assisted reproduction products in Europe, the Middle East, Africa, Asia-Pacific, and the Americas. It offers sperm processing, oocyte retrieval needles, micromanipulation pipettes, time-lapse systems, and evaluation tools, laser and imaging systems, IVF media and oil, embryo transfer, cryopreservation, and genomics kits. The company also provides eWitness and Labware products, such as dishes, pipettes, tubes, and VitroTemp. Vitrolife AB (publ) was incorporated in 1989 and is based in Gothenburg, Sweden.
